Related Experiment Videos

[Cyclophosphamide treatment in patients with systemic sclerosis]

Sylwia Chwieśko1, Otylia Kowal-Bielecka, Stanisław Sierakowski

  • 1Klinika Reumatologii i Chorób Wewnetrznych Akademii Medycznej w Białymstoku.

Postepy Higieny I Medycyny Doswiadczalnej (Online)
|June 13, 2006
PubMed

Insights

Systemic sclerosis (SSc) treatment remains challenging. This review examines Cyclophosphamide (CFX) use in SSc patients, noting its potential benefits for lung disease but also significant side effects.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Context:

  • Systemic sclerosis (SSc) is a complex autoimmune disease affecting connective tissues.
  • SSc involves skin and organ fibrosis, vascular damage, with unknown etiology and pathogenesis.
  • Current SSc treatments are limited, necessitating exploration of therapeutic options.

Purpose:

  • To review existing literature on the efficacy and safety of Cyclophosphamide (CFX) in Systemic Sclerosis (SSc) patients.
  • To evaluate the reported benefits of CFX, particularly for SSc-related interstitial lung disease.
  • To highlight the known side effects associated with CFX treatment in SSc.

Summary:

  • Cyclophosphamide (CFX) has shown potential benefits in managing Systemic Sclerosis (SSc), especially for interstitial lung disease.
  • The review synthesizes data on CFX's therapeutic actions in SSc.
  • However, the use of CFX is cautioned due to its associated adverse effects.

Impact:

  • This review provides a consolidated overview of Cyclophosphamide (CFX) for Systemic Sclerosis (SSc) management.
  • It aids clinicians in weighing the benefits against risks for SSc patients.
  • Highlights the need for further research into safer and more effective SSc therapies.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...